1984 Volume 32 Issue Supplement2 Pages 363-369
Fundamental and clinical studies on TA-058, a new injectable penicillin, were carried out.
1) Sensitivity of clinically isolated strains to TA-058 was tested by agar plate dilution method and compared with that of ABPC, CBPC and PIPC.
The antibacterial activity of TA-058 against most of clinical ioslates was found to be inferior to that of PIPC and similar to CBPC.
The peak MIC to H.influenzae was 0.1μg/ml, but sensitivities of β-lactamse producing strains were inferior to that of ABPC.
2) The maximum serum concentrations of TA-058 after 2.0g drip infusion in one hour were 66-112.5μg/ml (mean value 89.3μg/ml) and the mean values after 2, 4 and 6 hours from the start of infusion were 26.0, 14.3, 6.9μg/ml respectively. The peak level of TA-058 in pleural effusion from patient with lung cancer, after 2.0g drip infusion was 37.5μg/ml.
3) TA-058 was administered to 6 patients with daily doses of 2.0-6.0g for 3-41 days and clnical and side effect were investigated.
The drug efficacy was excellent in 1, good in 1, fair in 1 and poor in 3 patients and the effective rate was 33.3%.
No side effect was observed in all patients.
